Background

Dicot Pharma, a pharmaceutical company based in Sweden, is developing LIB-01, a potential next-generation treatment for erectile dysfunction and premature ejaculation. The company aims to introduce a long-acting alternative with a differentiated safety and efficacy profile compared to existing market solutions, addressing a significant unmet medical need.

Transaction Overview

Corpura acted as the financial advisor in two consecutive rights issues of units, assisting Dicot Pharma in raising a total of SEK 226.9 million. Both rights issues were oversubscribed, marking two successful transactions for Dicot Pharma. The capital was secured through a structured issuance of shares and warrants, executed in multiple stages to ensure continued financing for the company's clinical development.

Outcome and Impact

The successful completion of both rights issues enabled Dicot Pharma to:

• Advance its LIB-01 program into clinical trials, marking a key step in pharmaceutical development.
• Secure long-term financing, supporting continued research, development, and regulatory progress.
• Attract strategic investors, reinforcing confidence in the company’s trajectory and market potential.

Corpura’s role in these transactions facilitated a structured and efficient capital raise, supporting Dicot Pharma’s continued development efforts.

Use of Proceeds – Key Milestones

The capital raised through the two rights issues has contributed to several key milestones in the development of LIB-01:

Advancement to Clinical Phase 2a Trials

• Completion of Phase 1 Trials: Conducted between August 2023 and April 2024, the Phase 1 clinical study demonstrated a favorable safety profile for LIB-01. Additionally, preliminary data indicated potential effects on erectile function, with reported improvements lasting up to 28 days post-treatment.
• Initiation of Phase 2a Trials: Following the successful Phase 1 results, Dicot Pharma commenced a Phase 2a clinical trial in November 2024. The double-blind, placebo-controlled study aims to evaluate the efficacy of LIB-01 in patients with erectile dysfunction. The trial includes 140 male participants across six clinics in Sweden, Denmark, and the Netherlands.

Expansion of Research and Development

• Exploration of New Indications: In June 2024, new research suggested that LIB-01 might influence factors related to metabolic diseases. As a result, Dicot Pharma filed a new patent application, potentially broadening the therapeutic applications of LIB-01 beyond sexual dysfunction.

Outlook

With the successful completion of the rights issues and key clinical milestones achieved, Dicot Pharma is positioned to continue advancing its LIB-01 program. The next phase will focus on further clinical trials and exploring additional therapeutic applications.